Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

NCT07292272 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: 606-25-FB
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Conditions

Hodgkin Lymphoma; Leukemia; Lymphoid Leukemia; Multiple Myeloma; Myeloid Leukemia; Monocytic Leukemia; Non-hodgkin Lymphoma; Other Hematologic Condition

Outcome Measures

Primary Outcomes (2)

• Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.

  Adherence will be measured by those who completed 120 minutes or more of moderate exercise per week based on Polar Heart Rate data and Exercise Diaries.

  6 Months from start of program

• Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.

  Adherence will be measured by those who completed 120 minutes or more of moderate exercise per week based on Polar Heart Rate data and Exercise Diaries.

  12 Months from start of program.

Study Arms (2)

Intervention Arm-Supervised

EXPERIMENTAL

intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Behavioral: Supervised Exercise and Coaching

Enhanced Usual Care-Virtual Gym

ACTIVE COMPARATOR

enhanced usual care arm, where survivors will get access to virtual gym membership only.

Behavioral: Virtual Gym Membership

Interventions

Supervised Exercise and Coaching BEHAVIORAL

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Intervention Arm-Supervised

Virtual Gym Membership BEHAVIORAL

This arm will get access to a virtual gym membership only

Enhanced Usual Care-Virtual Gym

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥50 years
• A history of hematological malignancy
• Participants must be able to and willingly give informed consent

You may not qualify if:

• Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
• Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
• Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
• Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \<10 ml/kg/min).
• Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
• Participants who do not plan to follow up at the participating center.

Sponsors & Collaborators

• University of Nebraska: lead

Study Sites (1)

University of Nebraska Medical Center

Omaha, Nebraska, 68008, United States

Location

MeSH Terms

Conditions

Hodgkin Disease; Leukemia; Leukemia, Lymphoid; Multiple Myeloma; Leukemia, Myeloid; Leukemia, Monocytic, Acute; Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Hematologic Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Leukemia, Myeloid, Acute

Central Study Contacts

Taylor Johnson

CONTACT

402-559-4596; taylora.johnson@unmc.edu

IIT OFFICE

CONTACT

402-559-4596; iitoffice@unmc.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2025
• First Posted: December 18, 2025
• Study Start: March 1, 2026
• Primary Completion (Estimated): August 1, 2031
• Study Completion (Estimated): March 1, 2032
• Last Updated: March 23, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)